Russ Lebovitz—CEO of Amprion & a pioneer in disruptive biotechnology—talks about Amprion’s groundbreaking prion early detection science and how it aims to bring significant impact in Alzheimer’s, Parkinson’s, and other neurodegenerative disease. Amprion’s early detection prion testing enables the tracking of all three prions (aka misfolded proteins) in the brain before the start of any clinical symptoms. The company is revolutionizing prion early detection testing for Alzheimer’s and Parkinson’s, launching an innovative pathway to enable drug development by matching personalized biomarker profiles.
Meet our CEO, Russ Lebovitz
We have great science, great people, and we’re trying to solve really difficult, but important problems. Amprion has developed incredibly exciting and novel technology that looks at overall brain health. We look at things related to Alzheimer’s and Parkinson’s.
What Amprion’s technology allows people to do is to track, in real time, how their brain is aging with respect to Alzheimer’s and Parkinson’s. And so, by understanding where you are on the spectrum, you can make changes. One could make changes from lifestyle, people believe that diet or exercise, other lifestyle changes. On the other hand, we believe that one could manage these diseases and their brain health through the next generation of drugs.
I’m most excited that Amprion offers a way for us to really address these terrible, terrible diseases, and the way that some people age and that their brains go long before their bodies do. And we can change this, we can help people to manage this. At Amprion, we help people do what we call preventive brain care, and quality brain aging. What we do can change the face of Alzheimer’s and Parkinson’s with this revolutionary medical biotechnology.